Directed WakeMed's Complex PCI/CTO Program beginning in 2014
As of 2014 · Last known relationship
Islam M. Othman is an Associate Professor of Medicine at Duke whose documented work combines interventional cardiology, complex coronary intervention, and outcomes research. His clinical interests include percutaneous coronary intervention and chronic total occlusion treatment, including complex catheterization procedures at Duke Health. Earlier, he directed WakeMed’s Complex PCI/CTO Program beginning in 2014. His research has examined stent-based treatment, dual antiplatelet therapy, bleeding and ischemic risk, and PCI outcomes across demographic groups, including through the EVOLVE studies. Othman earned his M.D. from St. Matthew’s University School of Medicine in 2004, completed internal medicine training from 2004 to 2007, and then completed cardiovascular medicine and interventional cardiology fellowships at East Carolina University from 2007 to 2011.
Each topic is linked to its supporting source in Sources.
Training includes Interventional Cardiology Fellowship at East Carolina University, Brody School of Medicine, Cardiovascular Medicine Fellowship at East Carolina University, Brody School of Medicine, Internal Medicine Residency at Cone Health, and Internal Medicine Internship at University of Maryland, Baltimore, plus 6 more records.
Explore education and training2015
As of 2011
As of 2010
As of 2007
As of 2005
As of 2004
As of 2014
Grant involvement in the EVOLVE post-approval study of the SYNERGY everolimus-eluting coronary stent system[4]
2020 to 2024
Publication: “Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis)” (2023)[4]
2023
Publication: “Percutaneous Coronary Intervention in Men, Women, and Minorities With a Previous Coronary Artery Bypass Graft Surgery” (2023)[4]
2023
Publication: “Primary Results of the EVOLVE Short DAPT Study” (2021)[4]
2021
Publication: “Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents” (2019)[4]
2019
Publication: “TCT-406 Clinical Impact of DAPT Cessation Within 12 Months of Drug-Eluting Stent Implantation in Caucasians and Minorities” (2019)[4]
2019
Publication: “TCT CONNECT-381 Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent” (2020)[4]
2020